The company raised its full-year revenue guidance from a range of $58 billion to $61 billion to a range of $60 billion to $62 billion. The midpoint suggests a 35% increase in sales for the full year.

At current prices Novo Nordisk is a Strong Buy. It's good positioning in the promising weight loss segment, solid foundation ...

Viking Therapeutics (NASDAQ:VKTX), often touted as an attractive obesity play, shed more than a third of its value this week ...

The technology sector makes up just over a third of the S&P 500 with a 34% weighting. The tech sector includes the three ...